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severe liver involvement in a patient with a
complex rearrangement of ABHD5 promoter
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Bruno Giardina1,7 and Daniela Tavian1,2*Abstract
Background: α/β-hydrolase domain-containing protein 5 (ABHD5) plays an important role in the triacylglycerols
(TAG) hydrolysis. Indeed, ABHD5 is the co-activator of adipose triglyceride lipase (ATGL), that catalyses the initial step
of TAG hydrolysis. Mutations in ABHD5 gene are associated with the onset of Chanarin-Dorfman syndrome (CDS), a
rare autosomal recessive lipid storage disorder, characterized by non-bullous congenital ichthyosiform erythroderma
(NCIE), hepatomegaly and liver steatosis.
Case presentation: We describe here a 5-years-old Brazilian child who presented with NCIE at birth and diffuse
micro and macro-vesicular steatosis on liver biopsy since she was 2 years old. Molecular analysis of coding sequence
and putative 5′ regulatory region of ABHD5 gene was performed. A homozygous novel deletion, affecting the pro-
moter region and the exon 1, was identified, confirming the suspected diagnosis of CDS for this patient. RT-PCR
analysis showed that the genomic rearrangement completely abolished the ABHD5 gene expression in the patient,
while only a partial loss of expression was detected in her parents. This is the first report describing the identification of
a large deletion encompassing the promoter region of ABHD5 gene. The total loss of ABHD5 expression may
explain the early onset of CDS and the severe liver involvement. After molecular diagnosis, the patient started a
special diet, poor in fatty acids with medium chain triglycerides (MCT), and showed hepatic and dermatologic
improvement in spite of severe molecular defect.
Conclusions: This case report extends the spectrum of disease-causing ABHD5 mutations in CDS providing evidence
for a novel pathogenic mechanism for this rare disorder. Moreover, our preliminary data show that early diagnosis and
prompt treatment of neutral lipid accumulation might be useful for CD patients.
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Neutral lipid storage diseases (NLSDs) are a heterogeneous
group of lipid metabolic disorders, characterized by a deficit
in the degradation of the triacylglycerol and its abnormal
accumulation in cytoplasmic lipid droplets (LDs) present
in most tissues, including skin, liver and peripheral blood.
These rare autosomal recessive syndromes comprise the
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reproduction in any medium, provided the or[1], and the Neutral Lipid Storage Disease with Myopathy
(NLSDM; MIM 610717) [2,3]. The clinical symptoms of
CDS, described by Dorfman [4] in 1974 and by Chanarin
[5] in 1975, are characterized by non-bullous congenital
ichthyosiform erythroderma (NCIE) [6], hepatomegaly
and liver steatosis [7]. Muscle and hepatic enzymes levels
are often elevated. Other variable features are muscle
weakness, ataxia, neurosensory hearing loss, sub-capsular
cataracts, nystagmus, strabismus and mental retardation
[8]. Patients are sometimes born as collodion babies
[9,10]. The clinical diagnosis is based on observation of
Jordans’ bodies, characteristic cytoplasmatic vacuoles, in
the granulocytes [11].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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gene [1]. This gene is located on chromosome 3p21,
contains seven exons and codifies for the α/β-hydrolase
domain-containing protein 5, a protein of the esterase,
lipase and thioesterase subfamily. The human ABHD5 is
a 349 amino acid long protein with a molecular mass of
39 kDa, characterized by a pseudo-catalytic domain and
a lipid binding motif. In the pseudo-catalytic domain, the
usual serine is replaced by asparagine [12]. Consequently,
ABHD5 does not present enzymatic hydrolase activity but
co-activates adipose triglycerides lipase (ATGL) [13]. In
addition, ABHD5 preforms a lysophosphatidic acid acyl-
transferase (LPAAT) function [14]. It has been recently
demonstrated in mice that inflammatory stimuli increase
stress kinase levels in the liver. Subsequently, these cyto-
kines promote generation of phosphatidic acid (PA) from
LPAAT activity of ABHD5. PA activates stress kinases,
decreasing hepatic insulin signalling [14].
In the present study we describe the clinical and mo-
lecular characterization of a CDS patient from Brazil.
The genetic analysis of ABHD5 detected a novel dele-
tion in the promoter region, confirming the diagnosis of
Chanarin-Dorfman syndrome.
Case presentation
Our patient is a five-year-old Brazilian girl, second child
of non-consanguineous parents. Her perinatal period was
normal, but section was performed at 35 weeks of preg-
nancy. At birth she had a weight of 2.575 g, a length of
45 cm and an occipital frontal circumference of 34 cm.
Her skin was diffusely red and scaly, without hair, eye-
lashes and eyebrows. A diagnosis of congenital ichthyosis
was made at that time. Since the early days of life she was
followed by dermatologist, who prescribed an emolient
(aquaphor) topical cream. When she was 2 years old, in
order to start a new dermatological treatment with hydro-
cortisone, liver function tests were carried out revealing
mildly elevated values for aspartate aminotransferase test
(AST) and alanine aminotransferase test (ALT), while
normal values for gamma glutamyl transpeptidase (GGT),
serum albumin and bilirubin. Nevertheless massive hep-
atomegaly was detected. At the age of 2 years 5 months
liver biopsy showed diffuse micro and macro-vesicular
steatosis, without fibrosis (Figure 1A and B). At age of
3 years, multiple laboratory tests were performed: AST
and ALT were mildly elevated (85 IU/L and 77 IU/L, re-
spectively), GGT was elevated (28 IU/L), total bilirubin
(0.2 mg/dL) and serum albumin (4.4 g/dl) were normal,
alkaline phosphatase (AP) activity was of 93% and inter-
national normalized ratio (INR) was 1.03. At age of 4 years
3 months, Jordans’ bodies were observed in granulocytes
(Figure 1C and D), AST (46 IU/L) and serum albumin
(3.8 g/dl) were normal, ALT (64 IU/L) was slightly elevated,
GGT (35 IU/L) was increased, AP activity was of 72.5% andINR 1.2. Lipid analysis showed a normal level of total chol-
esterol (112 mg/dL) and triglycerides (73 mg/dL). She did
not present clinical evidence of myopathy, but there was a
mild elevation of creatine kinase. When she was 4 years
9 months, her liver was palpable 10 cm below the right cos-
tal margin and low fat diet with medium chain triglycerides
(MCT) was started, maintaining the usual dermatological
treatment. Topical ointment was started at birth, at which
age the skin lesions improved. At age of 5 years 5 months,
she had a weight of 19.1 kg and a length of 109.5 cm, her
skin was diffusely fine (Figure 1E and F) and liver was
palpable 7.5 cm below the right costal margin.
Since age of 2 years she had recurrent acute otitis media
and at age of 4 years mild conductive hearing loss was
detected by audiometry and impedanciometry.
Materials and methods
Genomic analysis
Genomic DNA was extracted from blood samples using
Gentra Puregene Kit (Qiagen). All ABHD5 exons (Gene-
Bank NG_007090.3) were PCR amplified [9]. Also the
sequence spanning 5 kb upstream from the ATG start
codon was analysed by long-range PCR using forward
primer 5′-GCAGCCAGGCCATTGAAGCC-3′ and reverse
primer 5′-CTCAGTGCAACGAGGAAGTT-3′. Amplifi-
cation was performed in a total volume of 50 μl containing
50 ng of genomic DNA, 10× PCR × Enhancer solution 1×
(Invitrogen), 10× PCR × Amplification Buffer, MgSO4
2 mM, dNTP 4 mM (Fermentas Inc), oligonucleotide
primers 1 μM and GoTaq® DNA polymerase (1 U; Pro-
mega Co). Thermal cycling (PTC-200; MJ Research Inc)
consisted of 5 min of initial denaturation at 95°C followed
by 36 cycles of 94°C (40 s), 56°C (30 s) and 72°C (1 min)
with a final extension step of 5 min at 72°C. All PCR prod-
ucts were purified and sequenced on 3730 DNA Analyzers
by the BigDye® Terminator V1.1 Cycle Sequencing Kit
(Applied Biosystems). PROSCAN Program Version 1.7
was used to scan the putative promoter region of ABHD5
gene and RepeatMasker software to identify repeat ele-
ments near the deleted sequence.
Comparative RT-PCR
1 μg RNA isolated from PAXgene blood tubes by PAXgene
blood RNA kit (Preanalytix) was converted into cDNA.
50 ng of cDNA were used to perform RT-PCR amplifi-
cation of ABHD5 mRNA [9]. Integrity of RNA and
comparable cDNA synthesis in all samples tested were
confirmed using glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) gene expression.
Results
ABHD5 gene analysis detected a 3955 bp homozy-
gous novel deletion associated with a 26 bp insertion
(NG_007090.3: g.43728907_43732862del3955ins26). The
Figure 1 Clinical phenotype of CDS patient. A and B) Liver biopsy stained with Trichrome- Magnification 100× and with Hematoxylin and
Eosin (HE)-Magnification 200×; C and D) Buffy coats stained with May-Grünland Giemsa (MGG) from control subject and patient: Jordans’ bodies
can be detected only in patient’s granulocytes-Magnification 100×; E and F) Erythema and fine desquamation of the skin on entire body surface.
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of the ATG start codon and also the exon 1 (Figure 2A
and B). This mutation was submitted to GenBank (acces-
sion number KF169942).
Proscan 1.7 software was used to identify the promoter
region, from the ATG start codon until 5000 bp upstream.
Two putative sequences were identified: the first was lo-
calized at 0.3 kb and the second at 5 kb, both comprising
transcription factors as AP-2, Sp1, GCF, NF-D and UCE.2
(Figure 2C). The large deletion completely removed thefirst putative promoter region. A comparative ABHD5
RT-PCR analysis was performed from the peripheral blood
of the CDS patient, her parents and a control subject to
evaluate whether the mutation could affect gene expression.
In the cDNA from patient, no ABHD5 mRNA could be
detected. In parents, only a partial decrease of ABHD5
mRNA level was observed in comparison with control
cDNA sample (Figure 2D).
In order to verify whether the deletion could be deter-
mined by the presence of repeat sequences, the analysis
Figure 2 Identification of ABHD5 large deletion. A) Diagram of the large deletion identified in Brasilian patient. Normal sequence of ABHD5
and promoter region is aligned with the deleted sequence. B) Scheme of rearrangement: deletion removes 3454 bp of the promoter sequence,
exon 1 and 331 bp of the intron 1. DNA repair was accompanied by an insertion of 26 bp (GCTGTCTGAAACCTTAGGATTTTGCA), indicated by a
dashed line, where the DNA breakpoints rejoined. Electropherogram of ABHD5 gene deletion in CDS patient is shown below the scheme. C)
Schematic representation of the promoter region identified at 0.3 kb from the ATG start codon with all transcription factors. D) ABHD5 expression
evaluated by comparative RT-PCR. Picture of gel shows lack of ABHD5 mRNA in the affected proband. M: 100-bp molecular weight marker. Lane I:
control. Lane II: CDS patient. Lane III: father. Lane IV: mother.
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RepeatMasker software. High density of Alu and LTR re-
peats has been identified in the ABHD5 promoter region,
although not strictly adjacent to the breakpoint flanking
region. Nevertheless, it cannot be excluded that these
repeat sequences could be involved in the molecular
mechanism causing this complex rearrangement, since it
is known that they usually promote recombination events.
Discussion
Chanarin-Dorfman syndrome is a multisystem genetic
disorder involving many tissues. Although the majorityof cases come from Mediterranean and Middle East re-
gions, CDS patients were also reported from Japan and
India. In this study, we have identified a novel homozy-
gous large deletion in a Brazilian patient, child of non-
consanguineous parents. The genomic rearrangement
affects the promoter region and the ATG start codon
of ABHD5 gene, totally abrogating its expression. Until
now, 63 CDS cases have been reported all over the world;
molecular diagnosis was performed for 52 of them.
Thirty-three different ABHD5 mutations have been de-
scribed, including deletions, insertions, missense, non-
sense and frameshift variations. Even though ABHD5
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ment, described in this study, is the first localized in
the promoter region and it results in the lack of mRNA
and protein production. To our best knowledge, 11 differ-
ent mutations causing truncated proteins have been de-
scribed in children younger than 6 years (21% of patients
for whom molecular diagnosis was done) [8,9,15-18]. These
genetic variations should lead to ABHD5 total or partial
loss and might explain the early onset of CDS. In particular,
two mutations, S17X and S33X, might result in the absence
of ABHD5 protein. The first one was identified in a two-
year-old patient and it was associated with development
of severe liver cirrhosis in the infancy [16]. The second
mutation was detected in a five-year-old girl [8]. This
patient was characterized by hepatomegaly, elevated levels
of CK and diffuse weakness. Similarly, the data reported
here suggest that the novel large deletion may be respon-
sible for early onset of the disease and for severe liver
involvement, documented by massive fat accumulation
observed in our patient. In fact, the biopsy reveals marked
steatosis, even though the liver function is normal so far,
without hepatic decompensation. The clinical course of all
young CDS patients will be important to follow in order
to monitor the hepatic damage. The lack of ABHD5
synthesis may result in an excessive and premature accu-
mulation of triacylglycerol in cytoplasmatic lipid droplets,
particularly in liver. As a result, the CDS patients are char-
acterized by hepatomegaly, steatosis and/or cirrhosis. In
these patients, ATGL is not mutated but its activity is
strongly decreased, since its activator is not produced.
In addition, the loss of ABHD5 protein also causes the
abolition of LPAAT activity and the lack of PA production.
Recent studies show that, in mouse liver, PA acts as mes-
senger to promote the activation of stress kinases (IKK-β,
S6K1 and mTOR) in response to inflammatory stimuli,
such as high-fat diet and lipopolysaccharide treatment. In
ABHD5 knockdown mice, the abrogation of PA synthesis
results in the decrease of activity of this pathway, causing
severe hepatic involvement [14]. It would be important to
investigate in human, and in particular in CDS patients, if
the lack of PA synthesis increases liver injury.
Whereas there is not specific pharmacologic treatment
for CDS, some authors recommended a low fat diet sup-
plemented with MCT to improve the liver findings and
a treatment with emollients for ichthyosis. A special diet
in the infancy would decrease the liver size and normalize
the hepatic enzymes. To date, 10 children, younger than
6 years (17% of patients), were put on a low fat diet and
4 of them showed a decrease of liver size [16,19-21]. A
six-year-old girl, CD patient who showed hepatomegaly,
started a diet supplemented with MCTand, after 4 months,
the liver size was decreased [19]. A reduction of liver fibro-
sis and a normalization of hepatic enzymes were observed
in a two-year-old patient, after treatment with a low fat dietcombined with the use of ursodeoxycholic acid (UDCA)
and vitamin E [16]. In 1997 Kakourou et al. described liver
decreased by 50% in a three-year-old boy after a medium-
chain TG diet. The same patient, at age of 8 years and still
on the low fat diet, showed a normal liver size [20]. Re-
cently, Mitra et al. reported a three-year-old CDS patient
who presented hepatomegaly (10 cm below the costal
margin) and mild splenomegaly and who was put on a
low fat diet with UDCA and vitamin E. After 1 year, liver
size decreased (4 cm below the costal margin) and spleno-
megaly was not available [21]. Similarly, our patient started
using UDCA, vitamin E and a special diet, poor in fatty
acids with MCT. 1 year after treatment, the child showed
an improvement of liver size (from 10 cm to 7.5 cm below
the costal margin) and skin condition.Conclusions
For the first time, our study provides evidence that complex
genomic rearrangements of ABHD5 promoter may be
associated with CDS onset. Therefore, the ABHD5 complete
molecular screening, comprising the promoter region, is
important in order to validate the clinical diagnosis and,
although the role of special diet remains controversial, an
early initiation of low fat diet might improve the liver
condition. Additional studies are warranted to clarify
the benefits of low fat diet in CDS patients. Moreover, will
be of great interest to evaluate possible dermatological
improvement.Consent
Informed consent for genetic analysis was obtained from
the study participants. Moreover, as the patient is a child,
written informed consent was obtained from her mother
for publication of this Case report and any accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
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